Mitchell C. Liu

600 West 10th Ave
Vancouver, BC V5Z4E6, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Response to "Re: O'Reilly et al. On CTV utilization in non-spine bone oligometastases treated with SABR".

Response to "Re: O'Reilly et al. On CTV utilization in non-spine bone oligometastases treated with SABR".

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 18, 2026

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 21, 2026

Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials.

Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials.

Journal: Radiation oncology (London, England)

Published: January 26, 2026

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Journal: International journal of radiation oncology, biology, physics

Published: October 24, 2025

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 17, 2025

Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial.

Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial.

Journal: BMC cancer

Published: September 23, 2025

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease.

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease.

Journal: Cancer letters

Published: August 19, 2025

Evaluating the Oncologic and Safety Outcomes of High-Dose Palliative Radiation Treatment with 30 Grays in Five Fractions.

Evaluating the Oncologic and Safety Outcomes of High-Dose Palliative Radiation Treatment with 30 Grays in Five Fractions.

Journal: Cureus

Published: August 07, 2025

Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System.

Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System.

Journal: Cancers

Published: July 29, 2025

RAPid simPLE (RAPPLE) Targeted Radiation Treatment Versus Whole Brain Radiation Therapy: A Retrospective Cohort Study of Matched Patients With Brain Metastases and Poor Prognosis.

RAPid simPLE (RAPPLE) Targeted Radiation Treatment Versus Whole Brain Radiation Therapy: A Retrospective Cohort Study of Matched Patients With Brain Metastases and Poor Prognosis.

Journal: Advances in radiation oncology

Published: July 15, 2025

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2025

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 27, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026